603 related articles for article (PubMed ID: 33463028)
21. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
Wiecek W; Karcher H
PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
[TBL] [Abstract][Full Text] [Related]
24. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
25. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
26. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
28. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
29. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
30. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
31. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
[TBL] [Abstract][Full Text] [Related]
32. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
George DJ; Hessel C; Halabi S; Michaelson MD; Hahn O; Walsh M; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; Morris MJ; Choueiri TK
Oncologist; 2019 Nov; 24(11):1497-1501. PubMed ID: 31399500
[TBL] [Abstract][Full Text] [Related]
34. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
[TBL] [Abstract][Full Text] [Related]
36. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
Maruzzo M; Pierantoni F; Bortolami A; Palleschi D; Zivi A; Nicodemo M; Sartori D; De Vivo R; Zustovich F; Bimbatti D; Pastorelli D; Vultaggio GD; Soraru' M; Ballestrin M; Modonesi C; Randisi P; Barile C; Perri G; Basso U; Zagonel V
Target Oncol; 2022 Jul; 17(4):467-474. PubMed ID: 35751733
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Flaifel A; Xie W; Braun DA; Ficial M; Bakouny Z; Nassar AH; Jennings RB; Escudier B; George DJ; Motzer RJ; Morris MJ; Powles T; Wang E; Huang Y; Freeman GJ; Choueiri TK; Signoretti S
Clin Cancer Res; 2019 Oct; 25(20):6080-6088. PubMed ID: 31371341
[TBL] [Abstract][Full Text] [Related]
38. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Choueiri TK; Hessel C; Halabi S; Sanford B; Michaelson MD; Hahn O; Walsh M; Olencki T; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; George D; Morris MJ
Eur J Cancer; 2018 May; 94():115-125. PubMed ID: 29550566
[TBL] [Abstract][Full Text] [Related]
39. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
Iacovelli R; Ciccarese C; Facchini G; Milella M; Urbano F; Basso U; De Giorgi U; Sabbatini R; Santini D; Berardi R; Santoni M; Bracarda S; Massari F; Masini C; De Tursi M; Ricotta R; Buti S; Zustovich F; Sepe P; Rossetti S; Maruzzo M; Cortesi E; Tortora G; Procopio G
Target Oncol; 2020 Aug; 15(4):495-501. PubMed ID: 32671807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
